Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Contact persons
Help
Publ. Version/Full Text
Postprint
DOI
 |
Open Access Green |
as soon as is submitted to ZB.
Fibroblast growth factor 21 – metabolic role in mice and men.
Endocr. Rev. 38, 468-488 (2017)
ince its identification in 2000, the interest of scientists in the hepatokine fibroblast growth factor (FGF) 21 has tremendously grown, and still remains high, due to a wealth of very robust data documenting this factor’s favorable effects on glucose and lipid metabolism in mice. For more than ten years now, intense in vivo and ex vivo experimentation addressed the physiological functions of FGF21 in humans as well as its pathophysiological role and pharmacological effects in human metabolic disease. This work produced a comprehensive collection of data revealing overlaps in FGF21 expression and function but also significant differences between mice and men that have to be considered before translation from bench to bedside can be successful. This review summarizes what is known about FGF21 in mice and humans with a special focus on this factor’s role in glucose and lipid metabolism and in metabolic diseases, such as obesity and type-2 diabetes mellitus. We highlight the discrepancies between mice and men and try to decipher their underlying reasons.
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Review
Keywords
Nonalcoholic Fatty Liver; Serum Fgf21 Levels; Brown Adipose-tissue; Activated-receptor-gamma; Improves Insulin Sensitivity; Type-2 Diabetes-mellitus; Coronary-artery-disease; Beta-klotho Expression; Ppar-alpha Activation; Metabolic Syndrome
ISSN (print) / ISBN
0163-769X
e-ISSN
1945-7189
Journal
Endocrine Reviews
Quellenangaben
Volume: 38,
Issue: 5,
Pages: 468-488
Publisher
The Endocrine Society
Publishing Place
Bethesda, Md.
Non-patent literature
Publications
Reviewing status
Peer reviewed